These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16138006)

  • 41. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
    Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
    BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.
    Vink SR; Schellens JH; van Blitterswijk WJ; Verheij M
    Invest New Drugs; 2005 Aug; 23(4):279-86. PubMed ID: 16012787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
    Beer TM; Higano CS; Saleh M; Dreicer R; Hudes G; Picus J; Rarick M; Fehrenbacher L; Hannah AL
    Invest New Drugs; 2007 Dec; 25(6):565-70. PubMed ID: 17618407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized study.
    Ferrari AC; Stone N; Stock R; Bednar M; Esseesse I; Singh H; Baldwin Y; Mandeli J
    J Clin Oncol; 2002 Jan; 20(2):538-44. PubMed ID: 11786584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
    Liu G; Gandara DR; Lara PN; Raghavan D; Doroshow JH; Twardowski P; Kantoff P; Oh W; Kim K; Wilding G
    Clin Cancer Res; 2004 Feb; 10(3):924-8. PubMed ID: 14871968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
    Horti J; Figg WD; Weinberger B; Kohler D; Sartor O
    Oncol Rep; 1998; 5(4):893-6. PubMed ID: 9625840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
    J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
    Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
    BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
    Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered.
    Fosså SD; Vaage S; Letocha H; Iversen J; Risberg T; Johannessen DC; Paus E; Smedsrud T;
    Scand J Urol Nephrol; 2002 Feb; 36(1):34-9. PubMed ID: 12002355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.